Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
FCGR3A encodes a receptor for the Fc portion of immunoglobulin G, and it is involved in the removal of antigen-antibody complexes from the circulation, as well as other other antibody-dependent responses. Additionally we are shipping FCGR3A Proteins (25) and FCGR3A Kits (13) and many more products for this protein.
Showing 10 out of 292 products:
Human Polyclonal FCGR3A Primary Antibody for WB - ABIN657457
Dornan, Spleiss, Yeh, Duchateau-Nguyen, Dufour, Zhi, Robak, Moiseev, Dmoszynska, Solal-Celigny, Warzocha, Loscertales, Catalano, Afanasiev, Larratt, Rossiev, Bence-Bruckler, Geisler, Montillo, Wenger, Weisser: Effect of FCGR2A and FCGR3A variants on CLL outcome. in Blood 2010
Show all 2 references for ABIN657457
Human Monoclonal FCGR3A Primary Antibody for FACS - ABIN4896166
Hartl, Krauss-Etschmann, Koller, Hordijk, Kuijpers, Hoffmann, Hector, Eber, Marcos, Bittmann, Eickelberg, Griese, Roos: Infiltrated neutrophils acquire novel chemokine receptor expression and chemokine responsiveness in chronic inflammatory lung diseases. in Journal of immunology (Baltimore, Md. : 1950) 2008
Human Monoclonal FCGR3A Primary Antibody for FACS - ABIN4896175
Markel, Seidman, Besser, Zabari, Ortenberg, Shapira, Treves, Loewenthal, Orenstein, Nagler, Schachter: Natural killer lysis receptor (NKLR)/NKLR-ligand matching as a novel approach for enhancing anti-tumor activity of allogeneic NK cells. in PLoS ONE 2009
Human Monoclonal FCGR3A Primary Antibody for FACS, IHC (p) - ABIN1688969
Romano, Kusio-Kobialka, Foukas, Baumgaertner, Meyer, Ballabeni, Michielin, Weide, Romero, Speiser: Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients. in Proceedings of the National Academy of Sciences of the United States of America 2015
used a combination of NMR and 1 mus (show TRPV6 Antibodies) all-atom computational simulations to identify unexpected contacts between the N45 N-glycan and CD16A polypeptide residues
We conclude that FCGR3A (show CD16 Antibodies) CNVs are a major risk factor for female sarcoidosis and FCGR3B (show CD16 Antibodies) CNVs may also affect the development of sarcoidosis.
FcgammaRIIIa V allele-restricted pathological complete response benefit from neoadjuvant trastuzumab plus lapatinib in HER2 (show ERBB2 Antibodies)+ breast cancer.
CD16 (show CD16 Antibodies)+ cells were significantly more frequent among Natural Killer (NK) cells negative for the inhibitory KIR (show GEM Antibodies) (iKIR) KIR2DL1 (show KIR2DL1 Antibodies), KIR2DL3 (show KIR2DL3 Antibodies), and KIR3DL1 (show KIR3DL1 Antibodies) than those positive for any one of these iKIR to the exclusion of the others, making iKIR+ NK cells poorer antibody dependent cellular cytotoxicity effectors than iKIR- NK cells.
The association of CD16a-inducible NK cell-selective transcripts CD160 (show CD160 Antibodies) and XCL1 (show XCL1 Antibodies) with kidney biopsies with antibody-mediated rejection provides evidence for NK cell CD16a activation in AMR (show GPR182 Antibodies).
expression of FcgammaR was not different between immune thrombocytopenia (ITP (show ITPA Antibodies)) and controls; the FCGR3A (show CD16 Antibodies) (158V/F) polymorphism, known to increase the affinity of FcgammaRIII (show CD16 Antibodies) to IgG, was over-represented in ITP (show ITPA Antibodies) patients
Increased fraction of CD16 (show CD16 Antibodies)(high) CD62L (show SELL Antibodies)(dim) neutrophils was shown to correlate with an increased survival rate.
Trastuzumab acidic variants had lesser binding to oncogene (show RAB1A Antibodies) protein HER-2 (HER2 (show ERBB2 Antibodies)) in comparison to the basic variants, and both acidic and basic variant showed no significant changes in their binding to soluble CD16a receptors.
FCGR3A expression is significantly upregulated in human masticatory mucosa during wound healing
Our findings indicate that CD16 (show CD16 Antibodies) 158F>V polymorphism may contribute to the increased risk of Idiopathic Thrombocytopenic Purpura, whereas CD32 (show FCGR2B Antibodies) 131H>R polymorphism may not be an important risk factor for Idiopathic Thrombocytopenic Purpura.
This gene encodes a receptor for the Fc portion of immunoglobulin G, and it is involved in the removal of antigen-antibody complexes from the circulation, as well as other other antibody-dependent responses. This gene (FCGR3A) is highly similar to another nearby gene (FCGR3B) located on chromosome 1. The receptor encoded by this gene is expressed on natural killer (NK) cells as an integral membrane glycoprotein anchored through a transmembrane peptide, whereas FCGR3B is expressed on polymorphonuclear neutrophils (PMN) where the receptor is anchored through a phosphatidylinositol (PI) linkage. Mutations in this gene have been linked to susceptibility to recurrent viral infections, susceptibility to systemic lupus erythematosus, and alloimmune neonatal neutropenia. Alternatively spliced transcript variants encoding different isoforms have been found for this gene.
, Fc fragment of IgG, low affinity III, receptor for (CD16)
, Fc gamma receptor III-A
, Fc-gamma RIII-alpha
, Fc-gamma RIIIa
, Fc-gamma receptor III-2 (CD 16)
, Fc-gamma receptor IIIb (CD16)
, fc-gamma RIII
, igG Fc receptor III-2
, immunoglobulin G Fc receptor III
, low affinity immunoglobulin gamma Fc region receptor III-A
, neutrophil-specific antigen NA